Page 12 - Pharmaceutical Firms

Anti-ageing tech, 'happiness medicines' to shape healthcare demand: Report

Wearables, anti-ageing hormone therapy, controlled psychedelics among 40 areas that will likely grow, it says

Indian pharmaceutical market registers a growth of 9.5% in March 2024

Moving annual turnover of Rs 1.98 tr between April 2023 and March 2024 marked a 6.5% growth, despite a 1% decrease in domestic market volumes

Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

NPPA revises ceiling prices of 923 scheduled drug formulations from April 1

The formulations in the new revised rate list include essential drugs such as painkillers, antivirals, antibiotics, antimalarials, and drugs for type 2 diabetes

Big plans ahead: Cipla looks for shot in the arm in niche areas

Open to licensing, collaboration in anti-diabetes space

Pharma firms bank on 'mother brands' to bolster new products: Report

A search conducted by Pharmarack showed that brands of any company, labelled under their mother brands, were observed to enjoy greater market share among their peers

Akums introduces room temperature treatment for sickle cell disease

sickle cell disease is a genetic blood disorder that causes severe pain and complications. It is particularly prevalent among tribal populations in India

Sun Pharma gets approval to sell acne treatment cream Winlevi in Australia

Collaboration with Cosmo enables rights for cream in several countries, says company

Pharma regulation: A complex problem

Medicines are critical for human wellbeing but its regulation, which is inherently complex, is even more challenging in India

Aurobindo Pharma to start production of Pen-G at its Andhra plant in Q1FY25

Aurobindo Pharma expects its Rs 2,400 crore Pen-G (penicillin) plant in Andhra Pradesh to start trial production in April and commercial production in a couple of months and ramping up of production will happen during the second quarter of next fiscal, a senior official of the city-based drug maker has said. Santhanam Subramanian, Chief Financial Officer of Aurobindo Pharma, also said the company is constructing a total of 10 new facilities which are expected to capitalise in the next one to two years. Currently, the firm has a total of 25 manufacturing and packaging facilities at various locations. The plant, which was approved under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country, will have a production capacity of around 15,000 tonnes annually. "We are doing the Pen-G project. We are in the process of installation and ...

Pharma industry bodies welcome govt's technical upgradation scheme

Drug manufacturers with annual turnovers below Rs 500 crore will get the financial assistance in upgrading their facilities to meet global standards

Sun Pharma recalls around 55,000 bottles of generic medication in US

Sun Pharma is recalling about 55,000 bottles of a generic medication to treat bowel disease in the American market, according to the US Food & Drug Administration (USFDA). As per the latest Enforcement Report by the US health regulator, New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the Mumbai-headquartered drug major, is recalling 54,960 bottles of Mesalamine extended-release capsules in the American market. Mesalamine delayed-release capsules are indicated for the treatment of mild to moderate ulcerative colitis. The affected lot of capsules have been manufactured by Sun Pharmaceutical Industries at its Mohali-based manufacturing plant and distributed in the US market by Sun Pharmaceutical Industries Inc. As per the USFDA, the company has initiated the Class II recall due to "Failed Dissolution Specifications". The company initiated the Class II recall on February 5 this year. As per the USFDA, a class II recall is initiated in a situation in which the use of, or

Noida police arrest CMD of pharma firm from B'luru for defrauding investor

The chairman and managing director of a pharmaceutical company has been arrested from Bengaluru for allegedly defrauding an investor of Rs 70 crore six years ago, Noida police said on Thursday. The pharma company has offices in Dubai and Chennai while the investor, a Delhi resident, runs a firm in Noida's Sector 18. Shakir Hussain alleged that he was tricked into investing money into Novo Health Care in 2017, 2018 and 2019 and was shown forged balance sheets of the company by the accused, Ramani Kalpati Ramachandran Venkata, a native of Chennai, according to the FIR. On December 5, 2023, Hussain lodged a complaint at Sector 20 police station alleging that the accused duped him of Rs 70 crore on the pretext of investment in his company, a police spokesperson said. "On the basis of the complaint, an FIR was registered in the case and the matter was investigated. On Wednesday, with the help of electronic surveillance and technical evidence, Venkata was held from Bengaluru (Karnataka),

Will pharma stocks continue their dream rally in FY25?

PRESCRIPTION FOR CAUTION: Analysts sound alarm on valuations after past year's recovery

Glenn Saldanha announced resignation as chairman of Glenmark Life Sciences

Glenmark Life Sciences Ltd on Wednesday said its Chairman Glenn Saldanha and non-executive director VS Mani have resigned following change in ownership of the company. Independent director Sridhar Gorthi has also tendered resignation, along with Saldanha and Mani, with effect from close of business hours on March 6, 2024, the company said in a regulatory filing. In his resignation letter shared on BSE by the company, Saldanha said his stepping down from the board and as chairman of the company is "pursuant to the transfer of ownership of the company by Glenmark Pharmaceuticals to Nirma Ltd". He is also stepping down as a member of the nomination and remuneration committee and operations committee of Glenmark Life Sciences. In September last year, Nirma Ltd had agreed to acquire 75 per cent stake in Glenmark Life Sciences for Rs 5,651.5 crore from Glenmark Pharmaceuticals. Mani also cited a similar reason for his resignation. On the other hand, Gorthi cited increasing professiona

US FDA approves Eyenovia's eye drops to reduce pain: Formosa Pharma

Eyenovia acquired US commercial rights of the drug last August from Formosa

Cadila Pharmaceuticals launches Tetra vaccine to prevent influenza

Cadila Pharmaceuticals on Monday said it has launched a vaccine to prevent influenza, a recurrent and widespread viral infection. The drug firm has introduced quadrivalent Cadiflu Tetra vaccine which has been approved by the DCGI (Drugs Controller General of India) for use in adults and children. The new vaccine targets four strains of the influenza virus subtype A and B, responsible for seasonal epidemics, the drug firm said in a statement. Developed using proprietary technology employing nano-sized particles, the vaccine mimics the external structure of the virus without containing intact genetic material, it added. "This breakthrough in vaccine development also holds promise for enhancing the protection of pregnant women against influenza, contributing to the overall well-being of both mother and child," Cadila Pharmaceuticals CMD Rajiv I Modi said. Influenza, commonly known as seasonal flu, is a highly contagious acute respiratory illness

Explained: Eli Lilly's 'miracle' weight-loss drug soon to enter India

The American pharmaceutical giant is set to introduce its obesity drug, a competitor to Nova Nordisk's Ozempic, in India as early as next year

Global pharma companies dominate Indian vaccine market: PharmaTrac report

Global pharmaceutical companies hold 60% of value share in India's vaccine market, outperforming domestically manufactured vaccines in terms of revenue

Sun Pharma to acquire 16.33% stake in US-based Surgimatix for $3 million

The transaction is expected to be completed by the end of February 2024, pending fulfilment of certain conditions